Compare Public Service Enterprise Group Incorporated Common Stock (PEG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Service Enterprise Group Incorporated Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? Public Service Enterprise Group Incorporated Common Stock trades at $69.9 (market cap $35.12B), while Recursion Pharmaceuticals Inc trades at $3.68 (market cap $2.08B). The key difference: Public Service Enterprise Group Incorporated Common Stock is far larger — about 16.9× Recursion Pharmaceuticals Inc's market cap, and Public Service Enterprise Group Incorporated Common Stock pays a 3.8% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Public Service Enterprise Group Incorporated Common Stock for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PEG | RXRX | |
|---|---|---|
Market Cap | $35.12B | $2.08B |
Volume | 4,400,164 | 19,700,033 |
Sector | Utilities | Health |
52-Week High | $86.95 | $6.79 |
52-Week Low | $66.56 | $2.84 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $59.61B | $1.60B |
Dividend Yield | 3.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Service Enterprise Group (PEG) trades at $70.47, down 0.41% on the day, showing neutral technical signals with support at $70 and resistance at $71. The company maintains solid fundamentals with a 17.53 P/E ratio and consistent earnings beats in recent quarters, though Q3 2026 results are pending. Revenue grew to $12.17B in 2025 with a healthy 16.04% net income margin, while analyst consensus remains mixed with a $83.40 price target suggesting potential upside.
PEG presents a stable utility investment with regulated growth and nuclear assets supporting a 6-8% earnings outlook. Key risks include regulatory approvals for capex plans and interest rate sensitivity. Institutional buying and a 15-year dividend growth streak add appeal, but recent CEO stock sales and proximity to 52-week lows warrant caution amid sector volatility.
RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported revenue of $74.26M in 2025 but posted a significant net loss of -$644.76M, reflecting negative profit margins. Recent news highlights strategic AI partnerships and pipeline expansion, though the stock faces high short interest and ongoing operational losses.
Outlook remains speculative with 40% analyst buy ratings but substantial financial losses. Key opportunities include AI-driven drug discovery partnerships, while risks involve cash burn, competitive pressures, and delayed profitability. The stock's valuation at 36.1x sales appears stretched given current financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Public Service Enterprise Group Incorporated Common Stock
Public Service Enterprise Group Incorporated is a New Jersey-based utility holding company operating through Public Service Electric and Gas Co. (PSE&G), which transmits and distributes electricity and distributes natural gas, and PSEG Power, which operates the Salem and Hope Creek nuclear generating stations. It also runs the Long Island Power Authority's electric system under contract via PSEG Long Island.
Read more on PEG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
